stockportfolio.pro
Allogene Therapeutics, Inc. (ALLO)
Healthcare · Biotechnology · NasdaqGS
Allogene Therapeutics, Inc. (ALLO) posted $0 in revenue for fiscal 2025 (down 100.0% year over year), with a net loss of $190.89M, per its SEC filings.
Data last refreshed June 15, 2026 from SEC filings · how we compute this
Allogene Therapeutics, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $114.09M | $156,000 | $95,000 | $22,000 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-211.50M | $-184.59M | $-316.38M | $-182.05M | $-340.41M | $-327.26M | $-257.59M | $-190.89M |
| Net margin | — | — | — | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
Source: Allogene Therapeutics, Inc. SEC filings (10-K).
Explore 8 years of Allogene Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ALLO in your portfolio →
Allogene Therapeutics, Inc. financial history by metric
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc. — frequently asked questions
What is Allogene Therapeutics, Inc.'s revenue?
Allogene Therapeutics, Inc. (ALLO) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Allogene Therapeutics, Inc. profitable?
No — ALLO reported a net loss of $-190.89M in fiscal 2025.
What is ALLO's P/E ratio?
Allogene Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Allogene Therapeutics, Inc. have?
As of fiscal year 2025, ALLO carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Allogene Therapeutics, Inc.'s market cap?
Allogene Therapeutics, Inc. (ALLO) has a market capitalization of about $636.81M, based on the latest data in our nightly-refreshed cache.
When does Allogene Therapeutics, Inc.'s fiscal year end?
ALLO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Allogene Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.